ENG/中
老虎证券
行情
交易
收费
优惠与活动
帮助
TigerAI
专栏
关于
登录
立即注册
Toggle
美股
详情
本页面由Tiger Trade Technology Pte. Ltd.提供服务
Portola Pharmaceuticals Inc.
18.03
0.0000
成交量：
- -
成交额：
- -
市值：
14.16亿
市盈率：
-4.76
高：
18.03
开：
18.03
低：
18.03
收：
18.03
52周最高：
31.73
52周最低：
5.31
股本：
7,851.73万
流通股本：
7,322.61万
量比：
- -
换手率：
- -
股息：
- -
股息率：
- -
每股收益(TTM):
-3.7842
每股收益(LYR):
-4.0621
净资产收益率：
-462.25%
总资产收益率：
-30.59%
市净率：
19.65
市盈率(LYR):
-4.44
数据加载中...
总览
公司
新闻资讯
公告
公司资料
公司名字：
Portola Pharmaceuticals Inc.
交易所：
NASDAQ
成立时间：
- -
员工人数：
- -
公司地址：
- -
官网：
http://www.portola.com
邮编：
- -
电话：
- -
传真：
- -
简介：
Portola Pharmaceuticals, Inc.是一家生物制药企业。公司致力于在血栓疾病以及其他血液疾病和发炎病症领域研发新的疗法，同时将该疗法商业化。该疗法主要用于当前没有或认证疗法选择有限的病人。公司于2003年9月在特拉华州注册成立。公司总部以及业务范围在加利福尼亚州的南旧金山市，并以一个部门生产经营。 公司两个主要项目用于解决血栓疾病和血凝块方面的问题。公司主要化合物是新型口服每日一次的贝曲西班，它是处于第三研发阶段凝血因子Xa的抑制剂，主要用于急性内科疾病患者静脉血栓栓塞的长期预防或预防性疗法。公司第二主要的候选研发药物是正处于概念取证阶段的PRT4445，它是一个主要用于逆转抗凝血生理活动的重组蛋白，该药主要用于使用抗凝血因子抑制剂治疗的患有不可控流血疾病或经历急诊外科手术的患者。公司第三种候选产品PRT2070是一种可口服的激酶抑制剂，该药物主要用于血液系统疾病、血液疾病、癌症及其他发炎类疾病。公司第四候选产品是 PRT2607，该药物由公司合作伙伴百健艾迪股份有限公司（Biogen Idec Inc.）开发研制，主要用于发炎类疾病。
{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/PTLA/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"PTLA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTLA\",,,,,undefined,":{"symbol":"PTLA","market":"US","secType":"STK","nameCN":"Portola Pharmaceuticals Inc.","latestPrice":18.03,"timestamp":1593633600000,"preClose":18.03,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":73226120,"shares":78517282,"eps":-3.784152,"marketStatus":"停牌","change":0,"latestTime":"03-23 12:45:37 EDT","open":18.03,"high":18.03,"low":18.03,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.784152,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1774296000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1369195200000,"exchange":"NASDAQ","adjPreClose":18.03,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTLA\",,,,,undefined,":{"symbol":"PTLA","floatShares":73226120,"roa":"-30.59%","roe":"-462.25%","lyrEps":-4.062079,"shares":78517282,"dividePrice":0,"high":18.03,"amplitude":0,"preClose":18.03,"low":18.03,"week52Low":5.31,"pbRate":"19.65","week52High":31.73,"institutionHeld":0,"latestPrice":18.03,"eps":-3.784152,"divideRate":0,"volume":0,"delay":0,"ttmEps":-3.784152,"open":18.03,"prevYearClose":23.88},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PTLA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2020-05-11","symbol":"PTLA","fiscalQuarterEnding":"2020/03","expectedEps":-0.74,"name":null,"time":"盘后","type":"earning","dateTimestamp":1589169600000,"reportTimeType":"post","actualEps":-0.88},{"market":"US","date":"2020-02-26","symbol":"PTLA","fiscalQuarterEnding":"2019/12","expectedEps":-0.89,"name":null,"time":"盘后","type":"earning","dateTimestamp":1582693200000,"reportTimeType":"post","actualEps":-1.24},{"date":"2019-11-05","symbol":"PTLA","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2019/09","expectedEps":-0.82,"defaultRemindTime":1572987600000,"name":null,"time":"盘后","dateTimestamp":1572930000000,"actualEps":null},{"date":"2019-08-07","symbol":"PTLA","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2019/06","expectedEps":-1.05,"defaultRemindTime":1565208000000,"name":null,"time":"盘后","dateTimestamp":1565150400000,"actualEps":-1.61},{"market":"US","date":"2019-05-08","symbol":"PTLA","fiscalQuarterEnding":"2019/03","expectedEps":-1.02,"name":null,"time":"盘前","type":"earning","dateTimestamp":1557288000000,"reportTimeType":"pre","actualEps":-1.02}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PTLA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PTLA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PTLA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PTLA","date":"2020-07-02","current":-4.764608,"percent":0.525692,"low":-8.397919,"twenty":-7.298314,"median":-5.390954,"eighty":-3.580615,"high":-1.552673,"avg":-5.298922,"sd":2.018062,"marketCap":1415666594},"quantilePoints":[],"updateTime":1774284337242},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.portola.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0207},{"period":"1month","weight":-0.055},{"period":"3month","weight":-0.047},{"period":"6month","weight":-0.0228},{"period":"1year","weight":0.1469},{"period":"ytd","weight":-0.0489}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Portola Pharmaceuticals, Inc.是一家生物制药企业。公司致力于在血栓疾病以及其他血液疾病和发炎病症领域研发新的疗法，同时将该疗法商业化。该疗法主要用于当前没有或认证疗法选择有限的病人。公司于2003年9月在特拉华州注册成立。公司总部以及业务范围在加利福尼亚州的南旧金山市，并以一个部门生产经营。 公司两个主要项目用于解决血栓疾病和血凝块方面的问题。公司主要化合物是新型口服每日一次的贝曲西班，它是处于第三研发阶段凝血因子Xa的抑制剂，主要用于急性内科疾病患者静脉血栓栓塞的长期预防或预防性疗法。公司第二主要的候选研发药物是正处于概念取证阶段的PRT4445，它是一个主要用于逆转抗凝血生理活动的重组蛋白，该药主要用于使用抗凝血因子抑制剂治疗的患有不可控流血疾病或经历急诊外科手术的患者。公司第三种候选产品PRT2070是一种可口服的激酶抑制剂，该药物主要用于血液系统疾病、血液疾病、癌症及其他发炎类疾病。公司第四候选产品是 PRT2607，该药物由公司合作伙伴百健艾迪股份有限公司（Biogen Idec Inc.）开发研制，主要用于发炎类疾病。","exchange":"NASDAQ","name":"Portola Pharmaceuticals Inc.","nameEN":"Portola Pharmaceuticals"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"PTLA\",market:\"US\",,,undefined,":null}}